Bioavailability
Valcyte is rapidly converted to ganciclovir, resulting in bioavailability of ≈60% — up to 10 times higher than that of ganciclovir capsules.4
Due to its significantly higher bioavailability, Valcyte tablets cannot be substituted for ganciclovir capsules on a one-to-one basis.4
Safety
Information
Reference:
4Valcyte® [product information]. Nutley, NJ: Roche Laboratories Inc.; January 2006.